Metformin in Alzheimer's dementia Prevention (MAP)
Trial Studying Metformin vs. Placebo in People with Mild Cognitive Impairment (55-90 Years of Age without Diabetes)
Sponsor: National Institute on Aging
Enrolling: Male and Female Patients
Study Length: 2 Years
Clinic Visits: 5
IRB Number: AAAS6912
U.S. Govt. ID: NCT04098666
Contact: Diego Zarate: (646) 946-9158 / daz2115@cumc.columbia.edu
Additional Study Information: MAP is a research study looking at whether metformin can help prevent memory decline for people with mild memory concerns. You may be able to join if: you are 55-90 years old, you or your loved ones have noticed some changes in your memory, and you are not already being treated for diabetes or dementia. Potential benefits: You will receive some of your blood test results. We can also share these results with your healthcare provider. Your participation may improve the prevention of dementia for future generations.
Investigator
Jose Luchsinger, MD
Do You Qualify?
Are you 55-90 years old? Yes No
Have you or your loved ones noticed some changes in your memory? Yes No
Are you already being treated for diabetes or dementia? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Diego Zarate
daz2115@cumc.columbia.edu
(646) 946-9158